Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2006-02-07
2006-02-07
Weber, Jon (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C530S300000, C514S002600, C435S068100
Reexamination Certificate
active
06995245
ABSTRACT:
The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein a transglutaminase reaction is employed to covalently and site specifically conjugate the EPO molecule to a non-antigenic hydrophilic polymer that can also be covalently linked to an organic molecule either of which modification increases the circulating serum half-life of the composition.
REFERENCES:
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 4904584 (1990-02-01), Shaw
patent: 5438040 (1995-08-01), Ekwuribe
patent: 6010871 (2000-01-01), Takahara et al.
patent: 6077939 (2000-06-01), Wei et al.
patent: 6322996 (2001-11-01), Haruya et al.
patent: 6331422 (2001-12-01), Hubbell et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6465694 (2002-10-01), Baudys et al.
patent: 6583272 (2003-06-01), Bailon
patent: 2004/0082765 (2004-04-01), Nakamura et al.
patent: 0539167 (1992-10-01), None
patent: WO 90/12874 (1990-11-01), None
patent: WO 94/28024 (1994-12-01), None
patent: WO 00/43492 (2000-07-01), None
patent: WO 01/02017 (2001-01-01), None
Sato, H. Advanced Drug Delivery Reviews 54: 487-504 (2002).
Groenen et al, “The carboxy-terminal lysine of xB-crystallin is an amine-donor substrate for tissue transglutaminase,”J. Biochem, 1992, pp 671-674, vol. 205.
Sata et al, “Site-Specific Modification of Interleukin-2 by the Combined Use of Genetic Engineering Techniques and Transglutaminase,”BIOCHEMISTRY, 1996, pp 13072-13080, vol. 35.
Gorman et al, “Structural Features of Glutamine Substrates for Human Plasma Factor XIIIa (Activated Blood Coagulation Factor XIII), ”The Journal of Biological Chemistry, 1980, pp 419-427, vol. 255, No. 2.
Dale et al, “Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface,”Letters to Nature, 2002, pp 175-179, vol. 415, Macmillan Magazines Ltd.
Grootjans et al, “Substrate Requirements for Transglutaminases,”The Journal of Biological Chemistry, 1995, pp 22855-22858, vol. 270, No> 39, The American Society for Biochemistry and Molecular Biology, Inc.
Gorman et al, “Structural Features of Glutamine Substrates for Transglutaminases,”The Journal of Biological Chemistry, 1981, pp 2712-2715, vol. 256, No. 6, U.S.A.
Fisher, “Erythropoietin: Physiology and Pharmacology Update,” Exp. Biol Med., 2003, pp 1-14, 228 (1).
Centocor, Inc.
Desai Anand
Townsend Guy Kevin
Weber Jon
LandOfFree
Formation of novel erythropoietin conjugates using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formation of novel erythropoietin conjugates using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formation of novel erythropoietin conjugates using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3651314